Literature DB >> 16265888

Uncomplicated malaria.

M P Grobusch1, P G Kremsner.   

Abstract

All symptoms and signs of uncomplicated malaria are non-specific, as shared with other febrile conditions, and can occur early or later in the course of the disease. In endemic areas, the presence of hepatosplenomegaly, thrombocytopenia and anaemia is clearly associated with malaria, particularly in children. Fever, cephalgias, fatigue, malaise, and musculoskeletal pain constitute the most frequent clinical features in malaria. Following single exposure to Plasmodium falciparum infection, the patient will either die in the acute attack or survive with the development of some immunity. Elderly individuals are prone to a more severe course of disease. The non-fatal P. vivax and P. ovale cause similar initial illnesses, with bouts of fever relapsing periodically, but irregularly over a period of up to 5 years. Renal involvement of a moderate degree is more common in mild falciparum malaria than initially suspected. The liver is also afflicted in mild disease, but organ damage is limited and fully reversible after parasitological cure. Whereas the cardiotoxic adverse effects of antimalarial chemotherapeutics are well known, clinically relevant cardiac involvement in humans is rare in severe disease and even rarer in uncomplicated falciparum malaria. Co-infection can aggravate malaria. There is a growing body of evidence that there is significant interaction in terms of mutual aggravation of the course of disease between HIV and malaria, particularly in pregnant women. Children with a high level of exposure to P. falciparum have a lower risk of developing atopic disorders.

Entities:  

Mesh:

Year:  2005        PMID: 16265888

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  26 in total

Review 1.  [Malaria].

Authors:  G Burchard
Journal:  Internist (Berl)       Date:  2006-08       Impact factor: 0.743

Review 2.  Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis.

Authors:  Li-Juan Zhou; Jing Xia; Hai-Xia Wei; Xiao-Jun Liu; Hong-Juan Peng
Journal:  Parasitol Res       Date:  2016-12-27       Impact factor: 2.289

3.  High prevalence of asymptomatic malaria in a tribal population in eastern India.

Authors:  Swagata Ganguly; Pabitra Saha; Subhasish K Guha; Asit Biswas; Sonali Das; Pratip K Kundu; Ardhendu K Maji
Journal:  J Clin Microbiol       Date:  2013-02-20       Impact factor: 5.948

4.  Elevated levels of IL-10 and G-CSF associated with asymptomatic malaria in pregnant women.

Authors:  Nana O Wilson; Tameka Bythwood; Wesley Solomon; Pauline Jolly; Nelly Yatich; Yi Jiang; Faisal Shuaib; Andrew A Adjei; Winston Anderson; Jonathan K Stiles
Journal:  Infect Dis Obstet Gynecol       Date:  2010-07-12

5.  Malarial parasite pathogenesis and drug targets.

Authors:  Paul D Roepe
Journal:  F1000 Biol Rep       Date:  2009-02-24

6.  The pathogenesis of malaria: a new perspective.

Authors:  Anthony R Mawson
Journal:  Pathog Glob Health       Date:  2013-04       Impact factor: 2.894

Review 7.  The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases?

Authors:  R Pullan; S Brooker
Journal:  Parasitology       Date:  2008-03-27       Impact factor: 3.234

Review 8.  Malaria parasite proteins that remodel the host erythrocyte.

Authors:  Alexander G Maier; Brian M Cooke; Alan F Cowman; Leann Tilley
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

Review 9.  Blood coagulation, inflammation, and malaria.

Authors:  Ivo M B Francischetti; Karl B Seydel; Robson Q Monteiro
Journal:  Microcirculation       Date:  2008-02       Impact factor: 2.628

10.  Spatial risk profiling of Plasmodium falciparum parasitaemia in a high endemicity area in Côte d'Ivoire.

Authors:  Giovanna Raso; Kigbafori D Silué; Penelope Vounatsou; Burton H Singer; Ahoua Yapi; Marcel Tanner; Jürg Utzinger; Eliézer K N'Goran
Journal:  Malar J       Date:  2009-11-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.